Sglt 2 denied as not medically necessary by Aetna?

Aetna's specific coverage criteria for sglt2 are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies SGLT2 Inhibitors on Medical-Necessity Grounds

Aetna's medical-necessity denials for SGLT2 inhibitors typically reflect a disagreement between the plan's reviewing clinician and the prescribing clinician about whether the patient's clinical profile meets the plan's internally defined medical-necessity criteria. Common triggers include: the plan's reviewer concluding that a preferred alternative would suffice, the clinical record not reflecting sufficient severity, or documentation gaps that leave the record ambiguous.

Medical-necessity denials are among the most successfully reversed on appeal when the clinical record is complete and the prescriber's rationale is clearly articulated.

## Federal Appeal Framework

• Internal appeal — file within the deadline on your denial notice. ERISA plans require Aetna to decide standard pre-service appeals within 30 days; urgent appeals within 72 hours. Request a copy of the specific clinical criteria and any internal review notes used to make the denial decision — you are entitled to this under ERISA.
• External review (ACA §2719 / ERISA §503) — if the internal appeal is denied, an independent external review organization with relevant clinical expertise reviews the decision. External reviewers apply medical standards, not just plan policy language. The external-review window is generally approximately four months from the original denial. Expedited review is available for urgent situations.

## Documentation to Gather

• Aetna's current medical-necessity criteria for SGLT2 inhibitors — request this directly from Aetna; it is your right under ERISA to receive the specific criteria applied. Address every criterion in your appeal.
• Diagnosis and comorbidity confirmation — chart notes, lab results, imaging, or specialist records confirming the condition being treated and any relevant comorbidities, documented with dates.
• Clinical severity documentation — office notes reflecting the patient's current clinical status, symptom burden, and objective markers of disease severity, per your treating clinician's assessment.
• Prior-treatment history with dates and outcomes — a chronological record of earlier therapies, with documented responses, side effects, or clinical failures, demonstrating that the patient's treatment history is consistent with the plan's step requirements.
• Prescriber letter of medical necessity — should address each of Aetna's stated criteria directly, explain why the SGLT2 inhibitor is appropriate for this patient's specific clinical profile, and reference support from the applicable guideline organization (e.g., relevant ADA, ACC/AHA, or KDIGO guidance) by organization name.

## Criteria-Mapping Structure

Build a one-to-one table in your appeal letter:

| Aetna Medical-Necessity Criterion | Supporting Chart Evidence | |---|---| | [Criterion 1 from Aetna policy] | [Specific chart fact, date, provider] | | [Criterion 2] | [Corresponding evidence] | | Prior therapy required | [Drug, dates, outcome] | | Specialist or guideline support | [Clinician specialty + guideline org name] |

## Key Argument

The appeal should reframe the denial as a documentation gap, not a clinical disagreement — present the record so completely that the reviewer has no basis to conclude the criteria are unmet. If Aetna's reviewer relied on criteria not disclosed to the patient or prescriber at the time of submission, challenge the denial on procedural grounds under ERISA §503's full-and-fair-review requirements.